Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TAR 001

Next Previous
X
Search
Drug Profile

TAR 001

Alternative Names: TAR-001

Latest Information Update: 24 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TargImmune Therapeutics
  • Class Antineoplastics; Imines; Polyethylene glycols; RNA
  • Mechanism of Action Apoptosis stimulants; Cytokine stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 21 Jun 2022 TargImmune therapeutics has patent protection in the US, Japan, Russia and Australia and patent pending in Brazil, Canada, China, Singapore, New Zealand, Mexico, Morocco, Israel, Philippines and South Africa
  • 20 Jun 2022 TargImmune Therapeutics plans a phase I trial for Solid tumours (TargImmune Therapeutics pipeline, June 2022)
  • 31 Mar 2022 Pharmacodynamics data from a preclinical study in Solid tumours released by TargImmune therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top